This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Pulmonary Alveolar Proteinosis폐포단백질증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: J84.0 | Special Copayment Reduction: V222
B. Synonyms—
C. Adult onsetLikelihood of first onset in adulthood very high — autoimmune pulmonary alveolar proteinosis occurs overwhelmingly in adults in their 30s–50s, and onset in children is rare. Secondary forms related to inhaled toxins or hematologic malignancies also mostly occur in adults.
1. History1958 Rosen, Castleman and Liebow reported cases of intrapulmonary lipoproteinaceous material accumulation → 1994 alveolar proteinosis confirmed in GM-CSF-deficient mice → 2001 anti-GM-CSF autoantibodies discovered → current advances in whole lung lavage and biologic therapy.
2. CausesClassified into three types: autoimmune (anti-GM-CSF autoantibodies, 90% of all cases), secondary (hematologic malignancies, inhaled toxins, immunodeficiency) and congenital (SFTPB, SFTPC, ABCA3, CSF2RA gene variants). Poor surfactant clearance due to alveolar macrophage dysfunction.
3. GeneticsThe autoimmune form is not hereditary. Congenital PAP is caused by variants of the SFTPB (autosomal recessive), SFTPC (autosomal dominant), ABCA3 (autosomal recessive) and CSF2RA (X-linked) genes. GM-CSF receptor defects are the key molecular mechanism.
4. General epidemiologyEstimated at about 3–7 per 1 million population. Autoimmune accounts for about 90% of all cases. Male:female = about 2–3:1. Age of onset 30s–50s. High proportion among smokers. Congenital form is extremely rare and manifests in the neonatal period.
5. PathophysiologyLack of GM-CSF signaling → impaired alveolar macrophage differentiation and function → poor degradation of surfactant phospholipids and proteins → accumulation of PAS-positive material within alveoli → impaired gas exchange → hypoxemia.
6. SymptomsSlowly progressive dyspnea, dry cough, fatigue. Some asymptomatic. High fever and hypoxemia in acute exacerbation. Fever and purulent sputum with superimposed infection (Nocardia, etc.).
7. SignsMild crackles on auscultation. Hypoxemia. Pulmonary function tests: restrictive ventilatory defect, reduced diffusing capacity (DLCO). Chest CT: bilateral ground-glass opacities, geographic pattern. BAL: milky turbid fluid, PAS-positive material.
8. ScreeningNo specific population screening. Chest HRCT is the initial tool for suspicion in patients with dyspnea of unknown cause. Elevated serum LDH and SP-D for reference. Need to recognize the possibility of PAP in patients with underlying hematologic malignancy or immunodeficiency.
9. DiagnosisChest HRCT (crazy-paving pattern). BAL cytology: PAS-positive enlarged macrophages, amorphous material. Serum anti-GM-CSF autoantibodies (titer >19 μg/mL). Lung tissue biopsy (transbronchial or surgical). Differentiation of autoimmune, secondary and congenital forms.
10. TreatmentWhole lung lavage (WLL) is the standard treatment. Autoimmune: inhaled GM-CSF (molgramostim), intravenous GM-CSF, plasma exchange, rituximab. Secondary: treatment of underlying disease. Spontaneous remission possible (about 10%). Infection prevention important.
11. Prognosis5-year survival after WLL treatment about 95%. Spontaneous remission about 10%. About 20–40% of patients need repeated WLL. Secondary PAP depends on the prognosis of the underlying disease. High mortality from opportunistic infections (Nocardia, Aspergillus).
12. PreventionSmoking cessation. Prevention of exposure to inhaled dust, silica and chemicals. Prevention of opportunistic infections in immunosuppressed patients. Early treatment of secondary causes. Regular pulmonary function monitoring.
13. ReferencesSeymour JF, Presneill JJ. Pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2002 … and 9 other references

1. History

Pulmonary Alveolar Proteinosis (PAP) was first described in 1958 by the American pathologists Samuel Rosen, Benjamin Castleman and Averill Liebow. Reporting that periodic acid-Schiff (PAS)-positive lipoproteinaceous material had accumulated within the alveoli in the lung tissue of 27 patients, they defined it as a new clinical syndrome. At the time, the etiology was entirely unknown, and it was understood simply as excessive accumulation of surfactant-like material within the alveoli.

In the 1960s–1970s, whole lung lavage (WLL) was introduced as a treatment, marking a major clinical turning point. In 1963, Ramirez-Rivera first attempted lung lavage via bronchoscopy, and subsequently whole lung lavage using one-lung ventilation under general anesthesia became the standard treatment. This treatment remains the first-line treatment for PAP today.

A revolutionary shift in the understanding of the pathophysiology came in 1994. When Jeffrey Whitsett and colleagues in the United States reported that pathologic findings identical to PAP appeared in mice lacking the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene, it became clear that GM-CSF is essential for alveolar macrophage differentiation and surfactant clearance. This discovery provided the key hypothesis for the pathogenesis of PAP.

In 2001, the group of Nakata and Kitamura in Japan discovered autoantibodies against GM-CSF (anti-GM-CSF autoantibody) in patients with autoimmune PAP. Neutralization of the biologic activity of GM-CSF by this antibody, impairing alveolar macrophage function, was shown to be the key mechanism of autoimmune PAP. This elucidated the etiology of the autoimmune form, which accounts for about 90% of all PAP patients, and measurement of serum anti-GM-CSF autoantibodies was introduced as a diagnostic tool.

Since the 2000s, treatment strategies that restore alveolar macrophage function by supplementing GM-CSF have been studied. Inhaled GM-CSF (molgramostim), which acts directly in the lung without being neutralized by anti-GM-CSF autoantibodies, received its first approval for autoimmune PAP in Europe in 2024. In addition, as a classification system for secondary PAP was established and gene variants causing congenital PAP (SFTPB, SFTPC, ABCA3, CSF2RA, etc.) were discovered, the etiologic classification of PAP was systematized.

In Korea, PAP case reports and treatment experience began to accumulate in domestic journals from the 2000s, and access to treatment improved through designation for rare disease Special Copayment Reduction (V222) registration. Whole lung lavage in Korea is performed through collaboration between thoracic surgery and pulmonology, and experience has accumulated at some tertiary hospitals.


2. Causes

Pulmonary alveolar proteinosis is broadly classified into three types according to etiology: autoimmune PAP, secondary PAP and hereditary/congenital PAP. This classification plays a key role in determining the treatment approach.

Autoimmune PAP (about 90% of all cases): Caused by serum anti-GM-CSF autoantibodies (mainly IgG) neutralizing the biologic activity of GM-CSF. GM-CSF is a cytokine essential for the differentiation, maturation, survival and surfactant catabolic function of alveolar macrophages. Anti-GM-CSF antibodies circulate not only in the alveoli but also in the blood, and why the disease occurs selectively only in the lungs is explained by lung-specific GM-CSF-dependent macrophage function. This form is more common particularly in smokers and men in their 30s–50s, and the specific mechanism of autoantibody induction has not yet been fully elucidated.

Secondary PAP (about 5–10% of all cases): Caused by a reduction in the number or function of alveolar macrophages due to various underlying diseases or exposures. Major causes include hematologic malignancies (myelodysplastic syndrome, leukemia, lymphoma), immunosuppression after solid organ transplantation, HIV infection, graft-versus-host disease, dust inhalation (silica, indium-tin oxide, titanium, aluminum) and exposure to cytotoxic anticancer drugs. In secondary PAP, anti-GM-CSF autoantibodies are negative, and PAP can improve with treatment of the underlying disease.

Congenital (hereditary) PAP: Caused by pathogenic variants in genes involved in surfactant metabolism or GM-CSF receptor signaling. Representative genes include SFTPB (surfactant protein B, autosomal recessive), SFTPC (surfactant protein C, autosomal dominant or de novo), ABCA3 (ATP-binding cassette transporter, autosomal recessive) and CSF2RA (GM-CSF receptor α subunit, X-linked). This form manifests in the neonatal period or infancy, and anti-GM-CSF autoantibodies are negative.

In all three forms, the final common pathway is impaired surfactant catabolism by alveolar macrophages. Surfactant is a phospholipid-protein complex that reduces alveolar surface tension to prevent lung collapse, and is normally continuously degraded and recycled by alveolar macrophages. When this process is interrupted, lipoproteinaceous material gradually accumulates within the alveoli and interferes with gas exchange.


3. Genetics

Autoimmune PAP is not a hereditary disease and is understood to arise from a complex interaction of environmental factors (smoking, dust inhalation, etc.) and immune dysregulation. An association with certain HLA types (HLA-DQ2, etc.) has been suggested in some studies, but a genetic predisposition has not been clinically established.

The genetics of congenital PAP are clearer. The SFTPB gene is located on chromosome 2 (2p11.2) and encodes surfactant protein B (SP-B). SP-B deficiency causes severe lung failure resembling neonatal respiratory distress syndrome and is inherited in an autosomal recessive manner. The founder mutation c.397delC (p.Pro133Glnfs) is the most common.

The SFTPC gene is located on chromosome 8 (8p21.3) and encodes SP-C. Most cases arise from autosomal dominant or new (de novo) variants and can manifest as interstitial lung disease at various ages from infancy to adulthood. The ABCA3 gene is located on chromosome 16 (16p13.3) and is involved in lamellar body formation. It is inherited in an autosomal recessive manner and shows diverse phenotypes ranging from severe neonatal lung failure to chronic interstitial lung disease in childhood.

The CSF2RA gene is located on the X chromosome (Xp22.3) and encodes the α subunit of the GM-CSF receptor. With X-linked inheritance, it manifests mainly in boys and is an important cause of congenital PAP. Variants of CSF2RB (22q12.3), which encodes the β subunit of the GM-CSF receptor, are also rarely reported. These congenital forms of PAP are diagnosed by gene panel testing or whole exome analysis, and genetic counseling is needed after confirmation.

Autoimmune PAP does not require genetic counseling, but in families of patients with congenital PAP, carrier testing and prenatal diagnosis according to the mode of inheritance may be considered. In particular, in SFTPB and ABCA3 deficiency, the parents are likely to be carriers, so family testing is important.


4. General epidemiology

Pulmonary alveolar proteinosis is a rare disease worldwide, with an estimated prevalence of about 3–7 per 1 million population. The most comprehensive epidemiologic data come from a nationwide cohort study conducted in Japan (Inoue et al., 2008), which reported a prevalence of about 6.2 per 1 million population and an annual incidence of 0.36.

Autoimmune PAP accounts for about 90% of all cases, and in sex distribution, men outnumber women by about 2–3 times. This is presumed to be related to sex differences in smoking rates. The age of onset is mostly in the 30s–50s, and onset in children is rare, under 5% of all cases. Incidence is higher in smokers than in nonsmokers, and there are reports that the proportion of active smokers at diagnosis reaches 60–70%.

By region, relatively many studies have been conducted in Japan, and case reports and cohort studies are accumulating in East Asia including Korea and China. In Korea, accurate prevalence data based on Health Insurance Review & Assessment Service (HIRA) data are limited, but patients are being identified through rare disease Special Copayment Reduction (V222) registration.

Secondary PAP accounts for about 5–10% of all cases and occurs at relatively high frequency in patients with hematologic malignancies. Some studies have reported a PAP co-occurrence rate of about 5–10% in patients with myelodysplastic syndrome (MDS). Secondary PAP related to occupational exposure (silica, indium, titanium, etc.) is reported sporadically in occupational disease cohorts.

Congenital PAP is very rare, and accurate epidemiologic data are lacking. SFTPB deficiency is one of the rare causes of neonatal respiratory distress, with an estimated occurrence of 1–2 per about 1 million newborns. The overall incidence of PAP is reported to be gradually increasing as rare disease registration systems are strengthened and awareness rises.


5. Pathophysiology

The core pathophysiology of pulmonary alveolar proteinosis is impaired surfactant catabolism by alveolar macrophages. Normally, surfactant secreted by type II alveolar epithelial cells is composed of phospholipids (phosphatidylcholine, phosphatidylglycerol, etc.) and proteins (SP-A, SP-B, SP-C, SP-D) and lowers alveolar surface tension to prevent end-expiratory alveolar collapse.

Under normal conditions, excess surfactant is taken up and degraded by alveolar macrophages. In this process, GM-CSF plays an essential role in the differentiation, activation and survival of alveolar macrophages. GM-CSF signaling activates the JAK2/STAT5, PI3K/Akt and RAS/MAPK pathways via the GM-CSF receptor (α/β heterodimer), inducing expression of the transcription factor PU.1 in macrophages. PU.1 regulates transcription of various enzymes required for surfactant catabolism (lysosomal hydrolases, lipolytic enzymes, etc.).

In autoimmune PAP, anti-GM-CSF IgG autoantibodies bind circulating GM-CSF and block receptor binding. As a result, alveolar macrophages do not receive sufficient GM-CSF signaling and their capacity for surfactant catabolism declines. PU.1 expression in alveolar macrophages decreases, and lysosomal function and lipolytic enzyme activity decline, so surfactant phospholipids and proteins accumulate progressively within the alveoli.

The accumulated material is PAS-positive amorphous lipoproteinaceous material that histologically fills the alveolar lumen and reduces the gas exchange surface. The oxygen diffusion distance between alveoli and capillaries increases, and ventilation-perfusion mismatch (V/Q mismatch) occurs, resulting in hypoxemia. Initially, dyspnea occurs only with exertion, but as the disease progresses, hypoxemia also occurs at rest.

Lack of GM-CSF signaling also impairs the pathogen defense function of alveolar macrophages. As a result, PAP patients have a markedly increased risk of opportunistic infections caused by Nocardia asteroides, Aspergillus, Cryptococcus, Mycobacterium and others. Opportunistic infections are one of the main causes of death in PAP patients.


6. Symptoms

The clinical symptoms of pulmonary alveolar proteinosis tend to progress slowly, and it often takes months to years from symptom onset to diagnosis. The severity of symptoms is proportional to the degree of intra-alveolar material accumulation and the severity of impaired oxygen exchange.

Dyspnea is the most common symptom, occurring in about 60–80% of all patients. It begins as mild dyspnea occurring only with exertion and, as the disease progresses, occurs with minor physical activity or even at rest. The rate of progression of dyspnea varies greatly between individuals.

Cough is mostly a dry, nonproductive cough, sometimes accompanied by a small amount of colorless, clear sputum. Hemoptysis is rare. Fatigue and generalized malaise are also common symptoms, and weight loss and reduced exercise capacity may occur.

About 20–30% of patients are asymptomatic or have mild symptoms at diagnosis and are sometimes discovered incidentally when chest imaging is performed for other reasons. Conversely, there are rare cases of hospitalization for acute or rapidly progressive lung failure, in which case differentiation from acute respiratory distress syndrome (ARDS) is needed.

Symptoms of superimposed infection: When an opportunistic infection, especially nocardiosis, develops, fever, chills, purulent sputum, chest pain and rapid worsening of dyspnea occur. Hemoptysis can occur with Aspergillus infection. When such infectious symptoms appear, immediate microbiological testing and appropriate anti-infective treatment are needed.

Cyanosis and clubbing may be observed in advanced hypoxemia but are often absent early on. Systemic symptoms (fever, night sweats, arthralgia, etc.) are more often associated with the underlying disease of secondary PAP (hematologic malignancy, etc.) than with autoimmune PAP.


7. Signs

The physical signs of pulmonary alveolar proteinosis are nonspecific, and findings are often normal early on. As the disease progresses, various respiratory and systemic signs appear.

Auscultation findings: In about 50% of patients, end-inspiratory crackles (fine crackles or velcro crackles) are heard over both lower lung fields. This finding is similar to idiopathic pulmonary fibrosis but tends to be less prominent in PAP. Wheezes or pleural friction rubs are rare.

Hypoxemia: Decreased oxygen saturation is observed at rest or with exertion. In severe cases, cyanosis may appear. On arterial blood gas analysis, hypoxemia (decreased PaO₂), normal or low PaCO₂ and respiratory alkalosis are characteristic.

Pulmonary function test findings: A restrictive ventilatory defect (decreased FVC, normal or increased FEV₁/FVC) and decreased diffusing capacity (DLCO) are characteristic. In severe patients, total lung capacity (TLC) and residual volume (RV) also decrease. Findings of airflow limitation (obstructive ventilatory defect) may appear in patients who also smoke.

Chest imaging findings: On plain chest X-ray, bilateral symmetric ground-glass opacities are characteristic but nonspecific. On high-resolution chest CT (HRCT), the crazy-paving pattern (a combined pattern of fine reticulation or interlobular septal thickening + ground-glass opacity) is the typical finding of PAP. This pattern is the most specific for PAP but can also appear in other lung diseases, so it alone does not confirm the diagnosis. Lesions show a geographic distribution and predominate in the middle to lower zones of both lungs.

Bronchoalveolar lavage (BAL) findings: BAL fluid is characteristically milky, turbid (milky or opaque) fluid, and PAS-positive amorphous lipoproteinaceous material is observed in the sediment after centrifugation. On microscopy, large, well-filled macrophages (foam cells) and amorphous granular material are characteristic. These findings provide strong evidence for the diagnosis of PAP.

Serum markers: Serum lactate dehydrogenase (LDH), surfactant protein D (SP-D), SP-A and carcinoembryonic antigen (CEA) may be elevated, but their diagnostic specificity is low. Serum anti-GM-CSF autoantibodies are a specific marker of autoimmune PAP.


8. Screening

Because pulmonary alveolar proteinosis has a low incidence and begins with nonspecific symptoms, there is no systematic screening program for the general population. However, clinical recognition and early diagnosis in certain high-risk groups are important.

Suspicion and early testing based on respiratory symptoms: It is important to perform chest HRCT when unexplained progressive exertional dyspnea and persistent dry cough last for several months or longer, especially in smokers. If a crazy-paving pattern is found on HRCT, PAP should be considered as a major differential diagnosis.

Patients with hematologic malignancies and immunodeficiency: When respiratory symptoms develop in patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) or lymphoma, patients receiving immunosuppressive therapy after solid organ transplantation, people with HIV infection and others, the possibility of secondary PAP must be considered. Because differentiation from opportunistic infection is important in this patient group, active bronchoscopic evaluation including bronchoalveolar lavage (BAL) is recommended.

Workers with occupational exposure: When respiratory symptoms develop in workers handling silica (quartz dust), indium-tin oxide (ITO), aluminum, titanium and the like, the possibility of occupational lung disease including PAP should be evaluated. Taking an occupational history is important for the diagnosis of secondary PAP.

Serum anti-GM-CSF autoantibody testing: Serum anti-GM-CSF autoantibody testing is useful for excluding PAP in patients previously diagnosed with interstitial lung disease of unknown cause. A positive result at the titer threshold (>19 μg/mL) is highly specific for autoimmune PAP.

Suspected congenital PAP (neonates and infants): When unexplained respiratory distress, persistent hypoxemia and growth failure appear in the neonatal period or infancy, a congenital disorder of surfactant metabolism (SFTPB, SFTPC, ABCA3, CSF2RA variants) should be suspected. In this case, gene panel testing plays a decisive role in diagnosis.


9. Diagnosis

Diagnosis of pulmonary alveolar proteinosis is made by a stepwise approach of clinical symptoms, imaging findings, bronchoalveolar lavage findings, serum anti-GM-CSF autoantibody measurement and, if necessary, lung tissue biopsy. Differentiating the autoimmune, secondary and congenital forms is essential for determining the treatment approach.

Chest HRCT: The first step in diagnosing PAP. The crazy-paving pattern (a combined finding of geographic ground-glass opacities and interlobular septal thickening) strongly suggests PAP. Lesions are distributed unevenly in both lungs and may be accompanied by consolidation. HRCT findings alone cannot confirm the diagnosis, but typical findings guide BAL and serologic testing.

Bronchoalveolar lavage (BAL): Bronchoscopic BAL is the most important noninvasive test for diagnosing PAP. If BAL fluid has a milky, turbid appearance, PAP is strongly suspected. In the sediment of centrifuged BAL fluid, PAS-positive, Sudan black B-positive amorphous lipoproteinaceous material and greatly enlarged foamy macrophages are characteristically observed. On electron microscopy, concentric or fingerprint-like lamellar structures (lamellar bodies) may be seen.

Serum anti-GM-CSF autoantibodies: A confirmatory tool for autoimmune PAP; a titer ≥19 μg/mL (or positive by the research institution's criteria) is highly specific for autoimmune PAP. Sensitivity of about 100% and specificity of about 98% are reported. This antibody is negative in secondary and congenital PAP and in normal controls. When autoimmune PAP is suspected, an approach of measuring serum anti-GM-CSF autoantibodies first, before BAL, is also reasonable.

Lung tissue biopsy: Transbronchial biopsy or surgical lung biopsy is needed when BAL findings are nondiagnostic or to exclude secondary causes (such as malignant infiltration). Histologically, filling of the alveolar lumen with PAS-positive fine granular material, relative preservation of alveolar architecture and mild alveolar wall inflammation are characteristic.

Additional tests to differentiate secondary PAP: Peripheral blood tests (blood counts, blood smear), bone marrow examination, diagnostic tests for hematologic malignancy, HIV testing, assessment of immune function, and investigation of occupational and environmental exposure history are needed. When congenital PAP is suspected, gene panel testing (NGS-based SFTPB, SFTPC, ABCA3, CSF2RA, etc.) is diagnostic.


10. Treatment

Treatment of pulmonary alveolar proteinosis is determined by the form (autoimmune, secondary, congenital) and severity. Because about 10% of autoimmune PAP undergoes spontaneous remission without treatment, observation for a certain period may also be considered when symptoms are mild.

Whole Lung Lavage (WLL): Currently the standard treatment for PAP. Under general anesthesia, a double-lumen endotracheal tube is inserted, and while one lung is ventilated, normal saline (10–30 L in total) is repeatedly instilled into and drained from the other lung to physically wash out intra-alveolar lipoproteinaceous material. In most cases, the other lung is treated 1–4 weeks after the first procedure. After treatment, about 40–60% of patients maintain long-term remission after a single procedure, but about 20–40% require repeated lavage because of relapse. Major complications include hypoxemia, pneumonia and pneumothorax, and it is important that it be performed at an experienced center.

Inhaled GM-CSF (molgramostim inhaler): In autoimmune PAP, inhaled administration of GM-CSF acts by restoring macrophage function locally in the lung. Because it is given by the inhaled route, it is less affected by neutralization by serum anti-GM-CSF autoantibodies. In the IMPALA clinical trial, inhaled molgramostim significantly improved treatment response rates, and it was approved in Europe in 2024 for the treatment of autoimmune PAP. The duration of administration is usually 12–24 weeks, and studies of long-term administration for relapse prevention are under way.

Subcutaneous/intravenous GM-CSF: Administration of molgramostim or sargramostim subcutaneously or intravenously, used as the main treatment alternative before approval of the inhaled formulation. With systemic administration, adverse effects such as arthralgia, fever and bone pain are more common than with inhaled administration.

Rituximab: An anti-CD20 antibody that acts by depleting B cells and reducing anti-GM-CSF autoantibody production. It is used as salvage therapy in patients with autoimmune PAP who do not respond to WLL or inhaled GM-CSF. Evidence is at the level of clinical case reports, and randomized controlled trials are still lacking.

Secondary PAP: Treatment of the underlying disease (hematologic malignancy, etc.) takes priority. Cases have been reported in which PAP improved along with treatment of hematologic malignancy by hematopoietic stem cell transplantation. When dust exposure is the cause, the exposure is stopped immediately.

Congenital PAP: Lung transplantation is the only definitive treatment. In SP-B deficiency, mechanical ventilatory support and pulmonary surfactant supplementation are needed immediately after birth, and lung transplantation is considered as soon as possible. Gene therapy research is under way.

Infection prevention and treatment: Early recognition of opportunistic infections such as nocardiosis and aspergillosis and appropriate antibiotic and antifungal treatment are important. Some experts recommend trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis in patients at high risk of opportunistic infection.


11. Prognosis

The prognosis of pulmonary alveolar proteinosis has improved greatly with advances in treatment, particularly the widespread use of whole lung lavage and the introduction of inhaled GM-CSF. Compared with a 5-year survival of about 30–50% before the whole lung lavage era, 5-year survival under modern treatment has improved to about 95% or more.

Prognosis of autoimmune PAP: About 10% of patients experience spontaneous remission, and even among patients requiring treatment, most show symptomatic improvement and recovery of physiologic function after whole lung lavage. Long-term remission is maintained after a single whole lung lavage in 40–60% of cases, while the remaining patients relapse within months to years and require repeated lavage. Inhaled GM-CSF is expected to play a role in preventing relapse after whole lung lavage and as first-line treatment in mild cases.

Prognosis of secondary PAP: Because it depends on the prognosis of the underlying hematologic malignancy, the success of treating the underlying disease is a more important prognostic factor than PAP itself. When accompanied by hematologic malignancies such as MDS and leukemia, the overall prognosis tends to be worse.

Opportunistic infections and prognosis: The occurrence of opportunistic infections such as nocardiosis and aspergillosis is one of the most important causes of death in PAP patients. Mortality is high when diagnosis is delayed or treatment is inadequate. There is hope that inhaled GM-CSF treatment may improve the ability to defend against infection by restoring alveolar macrophage function, but clinical proof is ongoing.

Quality of life and long-term follow-up: Exercise tolerance and oxygen requirements improve after whole lung lavage, but in the long term some patients do not achieve full recovery of lung function, and a mild reduction in diffusing capacity may persist. Recurrence and progression are followed with regular pulmonary function tests (every 6–12 months) and chest CT. Serum anti-GM-CSF autoantibody titers do not necessarily correspond to disease activity but are used as an adjunct in judging treatment response.

Prognosis of congenital PAP: SFTPB deficiency is fatal in the neonatal period without appropriate supportive treatment, and 5-year survival after lung transplantation is about 50–60%, with complications such as transplant rejection, infection and primary graft failure being the main problems. SFTPC and ABCA3 variants show wide phenotypic variability, ranging from mild to severe.


12. Prevention

No specific primary prevention for pulmonary alveolar proteinosis has been established. Preventing the onset of autoimmune PAP is currently impossible, but strategies to control known risk factors and prevent secondary forms are important.

Smoking cessation: Smoking is an important risk factor for autoimmune PAP, and 60–70% of PAP patients are smokers. Smoking cessation helps both to reduce the risk of PAP and to improve prognosis after diagnosis. The specific mechanism by which smoking promotes anti-GM-CSF autoantibody production is still unclear, but it is presumed to be mediated by lung epithelial injury and immune dysregulation.

Prevention of occupational dust and chemical exposure: Exposure to silica, indium-tin oxide (ITO), titanium dioxide, aluminum dust, detergent enzymes and the like is associated with the development of secondary PAP. Industrial hygiene measures such as wearing appropriate dust masks, local exhaust ventilation and workplace environmental monitoring are effective in preventing secondary PAP.

Management of patients with underlying hematologic malignancy and immunodeficiency: When respiratory symptoms develop in patients undergoing treatment for hematologic malignancy or immunosuppressive therapy, considering PAP early and including it in the differential diagnosis is important for halting the progression of secondary PAP early.

Prevention of congenital PAP: In congenital PAP related to SFTPB and ABCA3 gene variants, the birth of an affected fetus can be prevented through genetic counseling and preimplantation genetic testing (PGT) or prenatal genetic diagnosis. In families of patients already confirmed, carrier testing and reproductive counseling are important.

Prevention of opportunistic infections: In diagnosed PAP patients, minimize immunocompromised states and maintain vigilance for opportunistic infections (Nocardia, Aspergillus, etc.). Promptly starting diagnosis and treatment when symptoms of infection such as fever, new pulmonary infiltrates or purulent secretions appear prevents progression to severe infection.

Regular follow-up: After diagnosis, regular pulmonary function tests, chest CT and oxygen saturation monitoring detect recurrence early so that the timing of re-treatment is not missed. After inhaled GM-CSF treatment, follow-up is needed to assess treatment response and monitor adverse effects.


13. References

  1. Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med. 1958;258(23):1123-1142. DOI: 10.1056/NEJM195806052582301

  2. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166(2):215-235. PMID: 12119235.

  3. Inoue Y, Trapnell BC, Tazawa R, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177(7):752-762. DOI: 10.1164/rccm.200708-1271OC. PMID: 18202348.

  4. Tazawa R, Trapnell BC, Inoue Y, et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2010;181(12):1345-1354. DOI: 10.1164/rccm.200906-0978OC. PMID: 20167848.

  5. Trapnell BC, Nakata K, Bonella F, et al. Pulmonary alveolar proteinosis. Nat Rev Dis Primers. 2019;5(1):16. DOI: 10.1038/s41572-019-0066-3. PMID: 30846703.

  6. Suzuki T, Sakagami T, Young LR, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010;182(10):1292-1304. DOI: 10.1164/rccm.201002-0271OC. PMID: 20622029.

  7. Campo I, Mariani F, Rodi G, et al. Assessment and management of pulmonary alveolar proteinosis in a reference center. Orphanet J Rare Dis. 2013;8:40. DOI: 10.1186/1750-1172-8-40. PMID: 23497487.

  8. Bonella F, Bauer PC, Griese M, et al. Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med. 2011;105(12):1908-1916. DOI: 10.1016/j.rmed.2011.08.008. PMID: 21889879.

  9. Borie R, Danel C, Debray MP, et al. Pulmonary alveolar proteinosis. Eur Respir Rev. 2011;20(120):98-107. DOI: 10.1183/09059180.00001311. PMID: 21632797.

  10. Trapnell BC, Inoue Y, Bonella F, et al. Inhaled molgramostim therapy in autoimmune pulmonary alveolar proteinosis (IMPALA). N Engl J Med. 2020;383(17):1635-1644. DOI: 10.1056/NEJMoa2001725. PMID: 33085861.